About clarity pharmaceuticals ltd - CLRPF
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
CLRPF At a Glance
Clarity Pharmaceuticals Ltd.
National Innovation Centre
Eveleigh, New South Wales (NSW) 2015
| Phone | 61-2-9209-4037 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -41,639,716.18 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
CLRPF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.907 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.217 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
CLRPF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CLRPF Liquidity
| Current Ratio | 9.693 |
| Quick Ratio | 9.693 |
| Cash Ratio | 8.104 |
CLRPF Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -49.111 |
| Return on Equity | -53.099 |
| Return on Total Capital | -70.418 |
| Return on Invested Capital | -53.099 |
CLRPF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |